New legislation would place manufacturers of compounding drugs under FDA supervision. (posted July 22, 2013)
President’s Perspective: Will the Physician Payment Sunshine Act Shed Light on Conflicts of Interest?
What rheumatologists should know about complying with the PPSA when it goes into effect on August 1
How Rheumatologists Can Connect with Congress during August Recess
Tips for scheduling an in-person meeting and issues to discuss with lawmakers at their district offices
What Rheumatologists Need to Know About the Physician Payment Sunshine Act
The federal act mandates transparency within physician–industry relationship
Apply to Attend the ACR’s Advocates for Arthritis Day
Event educates legislators about the impact of rheumatic diseases and the importance of care provided by rheumatology professionals
Speak Out Rheum: How the U.K. and U.S. Healthcare Models Stack Up
A national, socialized medical system has significant advantages over the often-fragmented, unequally distributed U.S. system of healthcare, says one rheumatologist
Letters: Contract Negotiation Concerns
Since decisions by healthcare insurers can be draconian, fostering a collegial relationship with a healthcare insurer’s negotiator can help forge agreements between providers, payers
ACR Board of Directors Advocates for Rheumatology on Capitol Hill
Members meet with Congress this month to discuss access to rheumatology, access to treatments, and funding for research
Sequester Affects Rheumatologists on Two Fronts—Medicare Reimbursement and Research Funding
Rheumatologists are already feeling two effects from Congress’ inability to solve sequestration: a 2% reduction in Medicare reimbursements and slashed funding for research financed by the National Institutes of Health.
President’s Perspective: ACR Calls on Members to Advance Rheumatology
Members’ support and participation is needed to strengthen the ACR’s lobbying efforts with Congress
- « Previous Page
- 1
- …
- 65
- 66
- 67
- 68
- 69
- …
- 86
- Next Page »